Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases

Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases

Abstract Background In the INBUILD trial in patients with chronic fibrosing interstitial lung diseases (ILDs) and a progressive phenotype, nintedanib reduced the rate of ILD progression with adverse events that were manageable for most patients. We investigated the potential impact of immunomodulato...

Full description

Bibliographic Details
Main Authors: Vincent Cottin, Luca Richeldi, Ivan Rosas, Maria Otaola, Jin Woo Song, Sara Tomassetti, Marlies Wijsenbeek, Manuela Schmitz, Carl Coeck, Susanne Stowasser, Rozsa Schlenker-Herceg, Martin Kolb, the INBUILD Trial Investigators
Format: Article
Language:English
Published: BMC 2021-03-01
Series:Respiratory Research
Subjects:
Pulmonary fibrosis
Connective tissue diseases
Autoimmune diseases
Corticosteroids
Immunosuppressants
Online Access:https://doi.org/10.1186/s12931-021-01668-1

Internet

https://doi.org/10.1186/s12931-021-01668-1

Similar Items